NEW YORK (GenomeWeb News) – A clinical study targeting dysferlinopathy expected to cost $3 million has exceeded its patient recruitment goal, the Jain Foundation, which is funding the study, said today.

The Clinical Outcome Study for Dysferlinopathy has recruited 193 patients, passing the original goal of 150. The three-year project is being conducted in 14 centers and is led by Kate Bushby at Newcastle University and Laura Rufibach at the Jain Foundation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.